ResearcherUniversity of AntwerpActive in the last 2 years
Jonas R.M. Van Audenaerde
Matched on ORCID iD 0000-0002-5619-1913; OpenAlex author ID A5026684098. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 9
- Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. Last author DOI 10.1007/s00262-026-04343-w↗
- IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Last author DOI 10.1016/j.omton.2026.201316↗
- Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation. Co-author DOI 10.3390/cells14060450↗
- Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pharmthera.2022.108107↗
- Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.3390/cancers13050987↗
- Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Co-author DOI 10.1002/cti2.1165↗
- Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers11101597↗
- Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pharmthera.2018.04.003↗
- Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Co-author DOI 10.18632/oncotarget.18185↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Geert Roeyen · 8 shared papers, 2017–2026 · strength 1.20
- Paper Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. DOI 10.1007/s00262-026-04343-w↗
- Paper Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening an… DOI 10.3390/cells14060450↗
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316↗
- Evelien Smits · 8 shared papers, 2017–2026 · strength 1.04
- Paper Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening an… DOI 10.3390/cells14060450↗
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316↗
- Paper Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pharmthera.2022.108107↗
- Marc Peeters · 7 shared papers, 2017–2026 · strength 0.83
- Paper Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. DOI 10.1007/s00262-026-04343-w↗
- Paper Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pharmthera.2022.108107↗
- Paper Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. DOI 10.3390/cancers13050987↗
- Delphine Quatannens · 5 shared papers, 2020–2026 · strength 0.83
- Paper Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. DOI 10.1007/s00262-026-04343-w↗
- Paper Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening an… DOI 10.3390/cells14060450↗
- Paper Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pharmthera.2022.108107↗
- Hans Prenen · 4 shared papers, 2021–2026 · strength 0.72
- Paper Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. DOI 10.1007/s00262-026-04343-w↗
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316↗
- Paper Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. DOI 10.1016/j.pharmthera.2022.108107↗
- Christophe Deben · 4 shared papers, 2019–2026 · strength 0.64
- Paper Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening an… DOI 10.3390/cells14060450↗
- Paper IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. DOI 10.1016/j.omton.2026.201316↗
- Paper Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. DOI 10.3390/cancers13050987↗
- Annemie Bogaerts · 2 shared papers, 2019–2025 · strength 0.31
- Paper Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening an… DOI 10.3390/cells14060450↗
- Paper Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell… DOI 10.3390/cancers11101597↗
- Jinthe Van Loenhout · 3 shared papers, 2017–2020 · strength 0.23
- Paper Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 t… DOI 10.1002/cti2.1165↗
- Paper Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell… DOI 10.3390/cancers11101597↗
- Paper Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. DOI 10.18632/oncotarget.18185↗
- Ruben Verloy · 1 shared paper, 2025 · strength 0.23
- Angela Privat‐Maldonado · 1 shared paper, 2025 · strength 0.23
- Laura Gehrcken · 1 shared paper, 2026 · strength 0.22
- Sara R. Zanivan · 1 shared paper, 2021 · strength 0.11
- Andreas Domen · 1 shared paper, 2021 · strength 0.11
- Timon Vandamme · 1 shared paper, 2021 · strength 0.11
- Clare Y. Slaney · 1 shared paper, 2020 · strength 0.09
- Atsushi Masamune · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.